Physician profile
Michael Montgomery
NPI 1366553166
$1,969.75
in general payments reported to CMS, 2019-2025
23 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $295 · 2021: $177 · 2022: $173 · 2023: $270 · 2024: $474 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.96 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $455.84 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $308.98 | 2020-2025 | |
| Novo Nordisk INC | $268.42 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $211.65 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $98.84 | 2019-2021 | |
| Glaxosmithkline, LLC. | $97.88 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.20 | 2019-2022 | |
| Averitas Pharma INC. | $57.29 | 2024-2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.06 | 2022-2023 | Xifaxan |
| Exact Sciences Corporation | $38.98 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $36.90 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $31.42 | 2020-2022 | |
| Melinta Therapeutics, LLC | $28.16 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.52 | 2023 | Rexulti |
| Abbott Laboratories | $24.30 | 2025 | Freestyle Libre 2 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $22.76 | 2024 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $21.20 | 2020 | |
| Vanda Pharmaceuticals INC. | $20.22 | 2025 | Fanapt |
| Xeris Pharmaceuticals, INC. | $20.18 | 2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $18.04 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.35 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $14.83 | 2024 | Sotyktu |
| Paratek Pharmaceuticals, INC. | $13.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.